Envista (NYSE:NVST) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Envista (NYSE:NVST) posted its quarterly earnings data on Wednesday. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.07, FiscalAI reports. Envista had a return on equity of 7.87% and a net margin of 3.33%.The business had revenue of $730.50 million during the quarter, compared to the consensus estimate of $716.11 million. During the same period in the prior year, the company earned $0.26 earnings per share. The company’s revenue was up 7.1% compared to the same quarter last year. Envista updated its FY 2026 guidance to 1.500-1.550 EPS.

Here are the key takeaways from Envista’s conference call:

• Strong second-quarter results: Envista delivered 5% core sales growth, 28% adjusted EBITDA growth, 58% adjusted EPS growth to $0.41, and 158% free-cash-flow conversion. Growth was broad-based across both reporting segments and major geographies.
• Full-year guidance was raised and narrowed to 3.5%-4.5% core growth, 11%-14% adjusted EBITDA growth, and adjusted EPS of $1.50-$1.55; the expected tax rate was also reduced to approximately 26% from prior guidance.
• Equipment & Consumables grew 8.5% organically, supported by high-single-digit growth in consumables and diagnostics, continued share gains, pricing, and new products. Spark again grew at a double-digit rate, while new implant, orthodontic, and consumable product launches are intended to support future growth.
• Operational execution continued to improve profitability, with adjusted EBITDA margin expanding 230 basis points to 14.7% through manufacturing productivity, G&A savings, pricing, and favorable volume mix. The company also repurchased approximately 2.4 million shares and ended the quarter with net debt of 0.7 times adjusted EBITDA.
• Management expects slower reported growth in the second half, including flat to slightly negative core growth in the fourth quarter because of four fewer selling days. China’s upcoming ortho and implant volume-based procurement programs are expected to create significant price pressure, including roughly 10%-15% implant price compression and potentially greater pressure in orthodontics.

Envista Stock Performance

NYSE:NVST traded up $0.86 during midday trading on Friday, reaching $28.25. 2,447,072 shares of the company traded hands, compared to its average volume of 2,968,477. The firm has a market capitalization of $4.60 billion, a price-to-earnings ratio of 48.76, a price-to-earnings-growth ratio of 1.62 and a beta of 0.86. The company has a fifty day moving average price of $25.94 and a 200 day moving average price of $26.01. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.44 and a quick ratio of 2.06. Envista has a twelve month low of $18.77 and a twelve month high of $30.42.

Analyst Upgrades and Downgrades

Several analysts have weighed in on NVST shares. Robert W. Baird set a $34.00 target price on Envista in a report on Thursday. Citigroup initiated coverage on shares of Envista in a research report on Wednesday, April 15th. They set a “neutral” rating and a $29.00 target price for the company. Piper Sandler reiterated a “neutral” rating and issued a $28.00 target price (up from $26.00) on shares of Envista in a research note on Thursday. BMO Capital Markets started coverage on shares of Envista in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $27.00 price objective for the company. Finally, Mizuho set a $29.00 target price on Envista in a research note on Thursday. Six analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Envista has a consensus rating of “Hold” and a consensus price target of $29.31.

Institutional Trading of Envista

A number of large investors have recently modified their holdings of the company. Millennium Management LLC raised its holdings in Envista by 1,442.7% during the 4th quarter. Millennium Management LLC now owns 2,420,615 shares of the company’s stock worth $52,552,000 after buying an additional 2,263,712 shares during the period. Holocene Advisors LP acquired a new stake in Envista during the 2nd quarter valued at $43,936,000. Alliancebernstein L.P. boosted its holdings in shares of Envista by 34.0% during the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock worth $119,164,000 after purchasing an additional 1,547,656 shares during the period. Freestone Grove Partners LP purchased a new stake in Envista in the 4th quarter worth approximately $29,046,000. Finally, Balyasny Asset Management L.P. acquired a new position in Envista in the 3rd quarter worth about $24,260,000.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.